Bakas Spyridon, Shukla Gaurav, Akbari Hamed, Erus Guray, Sotiras Aristeidis, Rathore Saima, Sako Chiharu, Min Ha Sung, Rozycki Martin, Singh Ashish, Shinohara Russell, Bilello Michel, Davatzikos Christos
University of Pennsylvania, Department of Radiology, Center for Biomedical Image Computing and Analytics, University of Pennsylvania, USA.
Washington University, Department of Radiology, St. Louis, MO, USA.
Proc SPIE Int Soc Opt Eng. 2020 Feb;11315. doi: 10.1117/12.2566505. Epub 2020 Mar 16.
Glioblastoma, the most common and aggressive adult brain tumor, is considered non-curative at diagnosis. Current literature shows promise on imaging-based overall survival prediction for patients with glioblastoma while integrating advanced (structural, perfusion, and diffusion) multipara metric magnetic resonance imaging (Adv-mpMRI). However, most patients prior to initiation of therapy typically undergo only basic structural mpMRI (Bas-mpMRI, i.e., T1,T1-Gd,T2,T2-FLAIR) pre-operatively, rather than Adv-mpMRI. Here we assess a retrospective cohort of 101 glioblastoma patients with available Adv-mpMRI from a previous study, which has shown that an initial feature panel (IFP) extracted from Adv-mpMRI can yield accurate overall survival stratification. We further focus on demonstrating that equally accurate prediction models can be constructed using augmented feature panels (AFP) extracted solely from Bas-mpMRI, obviating the need for using Adv-mpMRI. The classification accuracy of the model utilizing Adv-mpMRI protocols and the IFP was 72.77%, and improved to 74.26% when utilizing the AFP on Bas-mpMRI. Furthermore, Kaplan-Meier analysis demonstrated superior classification of subjects into short-, intermediate-, and long-survivor classes when using AFPon Basic-mpMRI. This quantitative evaluation indicates that accurate survival prediction in glioblastoma patients is feasible by using solely Bas-mpMRI and integrative radiomic analysis can compensate for the lack of Adv-mpMRI. Our finding holds promise for predicting overall survival based on commonly-acquired Bas-mpMRI, and hence for potential generalization across multiple institutions that may not have access to Adv-mpMRI, facilitating better patient selection.
胶质母细胞瘤是最常见且侵袭性最强的成人脑肿瘤,在诊断时被认为无法治愈。当前文献显示,在整合先进的(结构、灌注和扩散)多参数磁共振成像(Adv-mpMRI)时,基于成像的胶质母细胞瘤患者总生存预测具有前景。然而,大多数患者在开始治疗前通常仅在术前接受基本的结构多参数磁共振成像(Bas-mpMRI,即T1、T1-Gd、T2、T2-FLAIR),而非Adv-mpMRI。在此,我们评估了一项回顾性队列研究中的101例胶质母细胞瘤患者,这些患者可获取先前研究中的Adv-mpMRI,该研究表明从Adv-mpMRI中提取的初始特征组(IFP)能够实现准确的总生存分层。我们进一步着重证明,仅从Bas-mpMRI中提取的增强特征组(AFP)也能构建出同样准确的预测模型,从而无需使用Adv-mpMRI。利用Adv-mpMRI方案和IFP的模型分类准确率为72.77%,而在Bas-mpMRI上使用AFP时,准确率提高到了74.26%。此外,Kaplan-Meier分析表明,在使用Basic-mpMRI上的AFP时,将受试者更好地分类为短期、中期和长期生存类别。这种定量评估表明,仅使用Bas-mpMRI对胶质母细胞瘤患者进行准确的生存预测是可行的,综合影像组学分析可以弥补Adv-mpMRI的不足。我们的发现为基于常规获取的Bas-mpMRI预测总生存带来了希望,因此对于可能无法获取Adv-mpMRI的多个机构而言具有潜在的推广价值,有助于更好地进行患者选择。